RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast

SummaryBackground. There is a need for reliable predictors of breast cancer aggressiveness that will further refine the staging classification and help guide the implementation of novel therapies. We have identified RhoC as being nearly always overexpressed in the most aggressive form of breast cancer, inflammatory breast cancer (IBC); in subsequent work we identified RhoC to be a promising marker of aggressive behavior in breast cancers less than 1 cm in diameter. We hypothesized that RhoC expression would identify aggressive, non-IBC tumors breast cancer patients at any stage with worse outcomes defined as recurrence and/or metastasis.Methods. We constructed four high-density tissue microarrays (TMAs) using 801 tissue cores from 280 patients. These tissues represent a wide range of normal breast and breast disease, including intraductal hyperplasia, ductal carcinoma in situ (DCIS), invasive carcinomas, and distant metastases. The TMAs were immunostained using a polyclonal anti-RhoC antibody developed in our laboratory. Cytoplasmic RhoC expression was scored as negative, weak, moderate, or strong by a previously validated scoring schema.Results. RhoC expression increases with breast cancer progression. All samples of normal breast epithelium had negative to weak staining, whereas staining intensity increased in hyperplasia, DCIS, invasive carcinoma, and metastases (Kruskal–Wallis p < 0.001). In patients with invasive carcinoma, high RhoC expression was associated with features of aggressive behavior including high histologic grade, positive lymph nodes, and negative hormonal receptor status. High RhoC expression was a predictor of overall survival in patients with breast cancer (log rank test, p = 0.002) and was associated with 100% increase in the risk of death as compared to patients with low RhoC expression. Importantly, high RhoC was an independent predictor of poor response to doxorubicin-based chemotherapy with a hazard ratio of 3.1 and a 95% CI of 1.2–7.7 (p = 0.02).Conclusion. RhoC expression increases with breast cancer progression and RhoC protein level in tumor tissue is strongly associated with biologically aggressive invasive carcinomas of the breast. RhoC expression, if validated, may identify patients who are less likely benefit from doxorubicin therapy and suggests RhoC overexpression as a new target for intervention.

[1]  Arul M Chinnaiyan,et al.  Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. , 2003, Journal of the National Cancer Institute.

[2]  S. Merajver,et al.  Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. , 2002, Molecular cancer therapeutics.

[3]  Y. Maehara,et al.  Higher expression of RhoC is related to invasiveness in non-small cell lung carcinoma. , 2003, Clinical Cancer Research.

[4]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[5]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[6]  X. Q. Chen,et al.  The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton , 1996, Molecular and cellular biology.

[7]  S. Merajver,et al.  Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. , 2003, Molecular cancer therapeutics.

[8]  D. Hayes.  Do we need prognostic factors in nodal-negative breast cancer? Arbiter. , 2000, European journal of cancer.

[9]  I. Ellis,et al.  Method for grading breast cancer. , 1993, Journal of clinical pathology.

[10]  M. Seabra.  Membrane association and targeting of prenylated Ras-like GTPases. , 1998, Cellular signalling.

[11]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  [Overexpression of the RhoC gene correlates with invasion and metastasis of hepatocellular carcinoma]. , 2004, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[13]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Merajver,et al.  WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer , 2003, Breast Cancer Research.

[15]  A. Hall,et al.  Rho GTPases and their effector proteins. , 2000, The Biochemical journal.

[16]  P. Casey,et al.  Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB* , 1997, The Journal of Biological Chemistry.

[17]  M. Rubin,et al.  Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. , 2001, The American journal of pathology.

[18]  Wei Wang,et al.  Expression and significance of RhoC gene in hepatocellular carcinoma. , 2003, World journal of gastroenterology.

[19]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[20]  G. Prendergast,et al.  Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton , 1994, Molecular and cellular biology.

[21]  P. Hall,et al.  Prognostic and predictive factors. , 2004, Methods in molecular medicine.

[22]  M. Rubin,et al.  Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. , 2000, Journal of the National Cancer Institute.

[23]  M. Sinensky,et al.  Recent advances in the study of prenylated proteins. , 2000, Biochimica et biophysica acta.

[24]  S. Narumiya,et al.  Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. , 1998, British Journal of Cancer.

[25]  Michael Bittner,et al.  Gene-expression profiling in human cutaneous melanoma , 2003, Oncogene.

[26]  S. Merajver,et al.  Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. , 2002, The American journal of pathology.

[27]  S. Merajver,et al.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. , 2000, Neoplasia.

[28]  Eric S. Lander,et al.  Genomic analysis of metastasis reveals an essential role for RhoC , 2000, Nature.

[29]  C. Nobes,et al.  Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia , 1995, Cell.

[30]  W. R. Bishop,et al.  In vivo prenylation analysis of Ras and Rho proteins. , 2001, Methods in enzymology.

[31]  Kazuhiro Yoshida,et al.  Expression of RhoC Is Associated with Metastasis of Gastric Carcinomas , 2003, Pathobiology.

[32]  C. Kelly,et al.  Treatment of metastatic disease of the tibia. , 2003, Clinical orthopaedics and related research.

[33]  Kyoko Arai,et al.  Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  C. Nobes,et al.  Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[35]  C J Marshall,et al.  Post-translational modifications of p21rho proteins. , 1992, The Journal of biological chemistry.

[36]  Daniel F. Hayes,et al.  Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.

[37]  G. Prendergast,et al.  Critical role of Rho in cell transformation by oncogenic Ras. , 1995, Oncogene.

[38]  Radhika Desai,et al.  ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix , 2003, The Journal of cell biology.

[39]  生駒 哲朗.  A definitive role of RhoC in metastasis of orthotopic lung cancer in mice , 2004 .

[40]  T. Nikaido,et al.  Up-Regulation of Small GTPases, RhoA and RhoC, Is Associated with Tumor Progression in Ovarian Carcinoma , 2003, Laboratory Investigation.